Featured Paper of the Month – April 2019.
Opioid use disorders are currently a serious health problem worldwide and yet prescription opioids remain as the most effective medications to treat pain. VK4-116, a highly selective dopamine D3 receptor antagonist, significantly inhibited acquisition of oxycodone self-administration behaviors and decreased oxycodone seeking in several rodent models. VK4-116 was also effective in a model of opioid-induced relapse and on diminishing the aversive effects of naloxone precipitated withdrawal. Notably, VK4-116 treatment had no effect on oxycodone-induced analgesia in the hot plate test. These results indicate that VK4-116 may be an effective non-opioid medication for the treatment of opioid use disorders, mitigating the development of dependence while preserving therapeutic usefulness of opioid analgesics.
Neuropsychopharmacology, 2018, ISSN: 1740-634X (Electronic); 0893-133X (Linking).